年度成就得主马骏教授:手把手教你发NEJM:CSCO2019

2019-09-21 不详 MedSci原创

第22届全国临床肿瘤学大会暨2019年CSCO学术年会于9月19日开幕,本届大会将2019年度成就奖颁发给了中山大学肿瘤防治中心 马骏教授 团队的“在局部晚期鼻咽癌患者中,同期放化疗前,吉西他滨+顺铂诱导化疗的III期、多中心、随机对照研究”。此次获奖研究内容发表于新英格兰医学期刊 (The New England Journal of Medicine;简称NEJM)杂志,同时也被选为2019年

第22届全国临床肿瘤学大会暨2019年CSCO学术年会于9月19日开幕,本届大会将2019年度成就奖颁发给了中山大学肿瘤防治中心 马骏教授 团队的“在局部晚期鼻咽癌患者中,同期放化疗前,吉西他滨+顺铂诱导化疗的III期、多中心、随机对照研究”。

此次获奖研究内容发表于新英格兰医学期刊 (The New England Journal of Medicine;简称NEJM)杂志,同时也被选为2019年的“Best of ASCO”。


在大会上,马骏教授向我们分享了他的NEJM投稿心得。

1.方案设计获认可
方案设计科学,有助于审稿顺利。
主要体现在几个方面:
·GP方案的选择:有前期结果
·对照组:标准治疗
·试验设计:随机对照,可信度高
·样本量计算:合理
·统计方法:严谨、遵循杂志要求
·数据解读:客观

2.统计方法要科学
NEJM不同于其他杂志,统计学要求严格,有两篇统计要求综述可参考。


(1)P值
除主要研究终点外,其余统计分析均不使用P值。两篇NEJM综述认为,很多临床研究文章中P值被过度滥用。因此在投稿NEJM时应特别小心P值的使用,符合杂志要求。

(2)生存分析
常用:单因素+多因素分析,而NEJM目前要求统一使用校正单因素分析。

(3)亚组分析
NEJM不主张进行亚组分析,研究主要看主要终点的比较,如用亚组分析比较,会有很多混杂因素,得出的结果可能会不可靠、不科学。
可利用森林图展示亚组分析结果,将亚组分析材料放在附件中作为参考。列出结果的置信区间,无需P值。

3.文字表达需简洁
主编及副主编亲自改稿,注重风格简洁,原论文题目为24词,被修改至8个词。投稿时应注意文字表达。


4.时间紧迫要合作
从投稿到接受仅30天,连续多次修回,每轮时限三四天。
可通过团队配合分工,减省时间。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009448, encodeId=f34d100944828, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Thu Aug 19 13:52:48 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641331, encodeId=164e1641331a3, content=<a href='/topic/show?id=250110149ec1' target=_blank style='color:#2F92EE;'>#马骏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101497, encryptionId=250110149ec1, topicName=马骏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=547322785431, createdName=12498c24m76暂无昵称, createdTime=Wed Apr 08 00:24:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080419, encodeId=bf0d20804196f, content=<a href='/topic/show?id=b43d10149883' target=_blank style='color:#2F92EE;'>#马骏教授#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101498, encryptionId=b43d10149883, topicName=马骏教授)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 09 11:24:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373112, encodeId=5f933e3112f4, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 23 22:57:02 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034959, encodeId=306610349594b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Sep 21 20:24:00 CST 2019, time=2019-09-21, status=1, ipAttribution=)]
    2021-08-19 ms9000001748316827

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009448, encodeId=f34d100944828, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Thu Aug 19 13:52:48 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641331, encodeId=164e1641331a3, content=<a href='/topic/show?id=250110149ec1' target=_blank style='color:#2F92EE;'>#马骏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101497, encryptionId=250110149ec1, topicName=马骏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=547322785431, createdName=12498c24m76暂无昵称, createdTime=Wed Apr 08 00:24:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080419, encodeId=bf0d20804196f, content=<a href='/topic/show?id=b43d10149883' target=_blank style='color:#2F92EE;'>#马骏教授#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101498, encryptionId=b43d10149883, topicName=马骏教授)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 09 11:24:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373112, encodeId=5f933e3112f4, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 23 22:57:02 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034959, encodeId=306610349594b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Sep 21 20:24:00 CST 2019, time=2019-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1009448, encodeId=f34d100944828, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Thu Aug 19 13:52:48 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641331, encodeId=164e1641331a3, content=<a href='/topic/show?id=250110149ec1' target=_blank style='color:#2F92EE;'>#马骏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101497, encryptionId=250110149ec1, topicName=马骏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=547322785431, createdName=12498c24m76暂无昵称, createdTime=Wed Apr 08 00:24:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080419, encodeId=bf0d20804196f, content=<a href='/topic/show?id=b43d10149883' target=_blank style='color:#2F92EE;'>#马骏教授#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101498, encryptionId=b43d10149883, topicName=马骏教授)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 09 11:24:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373112, encodeId=5f933e3112f4, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 23 22:57:02 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034959, encodeId=306610349594b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Sep 21 20:24:00 CST 2019, time=2019-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1009448, encodeId=f34d100944828, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Thu Aug 19 13:52:48 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641331, encodeId=164e1641331a3, content=<a href='/topic/show?id=250110149ec1' target=_blank style='color:#2F92EE;'>#马骏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101497, encryptionId=250110149ec1, topicName=马骏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=547322785431, createdName=12498c24m76暂无昵称, createdTime=Wed Apr 08 00:24:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080419, encodeId=bf0d20804196f, content=<a href='/topic/show?id=b43d10149883' target=_blank style='color:#2F92EE;'>#马骏教授#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101498, encryptionId=b43d10149883, topicName=马骏教授)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 09 11:24:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373112, encodeId=5f933e3112f4, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 23 22:57:02 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034959, encodeId=306610349594b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Sep 21 20:24:00 CST 2019, time=2019-09-21, status=1, ipAttribution=)]
    2019-09-23 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1009448, encodeId=f34d100944828, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c0e35449988, createdName=ms9000001748316827, createdTime=Thu Aug 19 13:52:48 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641331, encodeId=164e1641331a3, content=<a href='/topic/show?id=250110149ec1' target=_blank style='color:#2F92EE;'>#马骏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101497, encryptionId=250110149ec1, topicName=马骏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=547322785431, createdName=12498c24m76暂无昵称, createdTime=Wed Apr 08 00:24:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080419, encodeId=bf0d20804196f, content=<a href='/topic/show?id=b43d10149883' target=_blank style='color:#2F92EE;'>#马骏教授#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101498, encryptionId=b43d10149883, topicName=马骏教授)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Jun 09 11:24:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373112, encodeId=5f933e3112f4, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 23 22:57:02 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034959, encodeId=306610349594b, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Sep 21 20:24:00 CST 2019, time=2019-09-21, status=1, ipAttribution=)]
    2019-09-21 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

NEJM:POINT试验硬着陆

小卒中或TIA后90天内的缺血性卒中的风险为3-15%。在几项试验中,阿司匹林显示能够降低20%卒中复发风险。氯吡格雷通过P2Y12-受体途径阻断血小板聚集,能够协同阿司匹林的抗血小板聚集作用。在急性冠脉综合症中,阿司匹林联合氯吡格雷比单用阿司匹林能够更加有效地降低缺血事件的风险。

年终盘点:2018年NEJM杂志重磅级突破性研究成果

2018年NEJM杂志发表了很多非常有意义的重磅级研究成果,比如,免疫治疗为三阴性乳腺癌带来新希望,DNA测序可预测一线结核药物的敏感性 …… 今年NEJM上还有哪些亮点研究呢?跟小M一起来看吧! 【1】神药折戟!阿司匹林在糖尿病患者的一级预防中无用阿司匹林在冠心病二级预防中的作用毋容置疑。糖尿病与心血管风险增加有关,但是阿司匹林在糖尿病但无冠心病的患者中使用是否可获益目前还尚不清楚

NEJM重磅!FDA连环惊喜,新批准的两种靶向药使绝经前后乳腺癌患者均受益!

当前靶向治疗在肿瘤治疗领域中可谓是大放异彩,为众多肿瘤患者带来新希望,但是乳腺癌被称为靶向新药的“坟墓”,众多靶向新药在乳腺癌的治疗研究中遭遇滑铁卢,而今年的肿瘤学奥林匹克盛会--美国临床肿瘤学会(ASCO)年会上提出的一项报告则打破了目前靶向乳腺癌药物的困局,加州大学洛杉矶分校领导的一项研究发现,使用一种名为ribociclib(瑞博西尼)的药物与常见的激素疗法相结合,可将晚期乳腺癌患者的生存期

我的《新英格兰医学杂志》论文养成记

2018年1月4日,《新英格兰医学杂志》(NEJM)发表了复旦大学附属华山医院、国家老年疾病临床医学研究中心(华山)徐文东团队“健侧颈7移位术治疗中枢损伤后上肢痉挛瘫的临床试验”(2017年12月21日在线发表;详见《徐文东团队NEJM论著:“交叉移位”颈神经,治疗上肢痉挛瘫》)。这项研究是关于一项手术新技术的临床试验,是完全中国原创的全新治疗策略,一经发表便在学术界和患者中引起了巨大反响。本周,

NEJM:静脉溶栓时间窗扩大到9h

当前指南把缺血性卒中静脉溶栓治疗的事件限定在卒中发作4.5h 以内。这些指南的推荐意见主要是根据非增强 CT 筛选患者试验的 meta 分析结果。CT 灌注和灌注-弥散 MRI 能够发现卒中发作4.5h 后存活的脑组织,研究发现对于超过4.5h 但是如果存在可挽救脑组织的患者,静脉溶栓能够改善这些患者的功能预后。